These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 30937265)

  • 21. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities.
    Sanaei MJ; Pourbagheri-Sigaroodi A; Kaveh V; Sheikholeslami SA; Salari S; Bashash D
    Crit Rev Oncol Hematol; 2021 Jan; 157():103160. PubMed ID: 33220601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
    Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
    Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle.
    Masoumi E; Tahaghoghi-Hajghorbani S; Jafarzadeh L; Sanaei MJ; Pourbagheri-Sigaroodi A; Bashash D
    J Control Release; 2021 Dec; 340():168-187. PubMed ID: 34743998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
    Hegde UP; Mukherji B
    Cancer Immunol Immunother; 2017 Sep; 66(9):1113-1121. PubMed ID: 28497159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy.
    Shahvali S; Rahiman N; Jaafari MR; Arabi L
    Drug Deliv Transl Res; 2023 Jul; 13(7):2041-2056. PubMed ID: 36840906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy: a promising approach for glioma treatment.
    Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
    Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highlights into historical and current immune interventions for cancer.
    Cole K; Al-Kadhimi Z; Talmadge JE
    Int Immunopharmacol; 2023 Apr; 117():109882. PubMed ID: 36848790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
    Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
    Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
    Shen KY; Zhu Y; Xie SZ; Qin LX
    J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies.
    Matsueda S; Chodon T; Koya RC
    Adv Exp Med Biol; 2019; 1143():217-229. PubMed ID: 31338822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
    Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
    Ginefra P; Lorusso G; Vannini N
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
    Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
    J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.